More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo

Two Western biopharmas made headlines last week by entering deals with China-based biotechs around an emerging class of bispecifics, and the drumbeat continued early this week with more deals for other bifunctional antibodies.

The bigger deals drawing attention were around anti-PD-(L)1 x VEGF bispecifics, as BioNTech SE (NASDAQ:BNTX) acquired Biotheus Inc. for $800 million up front, and Merck & Co. Inc. (NYSE:MRK) took global rights to a program from LaNova Medicines Ltd. for $588 million...